Oxigene competition
Even though Oxigene is the leader in vascular targeting agents based on inhibition of tubulin polymerization in endothelial cells, my attention was caught recently by other drugs being developped as combretastatin analogs by 3 other companies:
-The most recent one is Medicinova, who recently acquired rights to a series of novels VAT from Angiogene pharmaceuticals, called ANG 600 series.
-A bigger player is Aventis with AVE8062, combretastation analog originally developped by Ajinomoto under the name AC7700
-The last is AstraZeneca who also acquired right from Angiogene and now develops ZD6126
For these last two, extensive preclinical work has been made on various animal models of cancer and AVE is in phase I.
All these compounds claim they exhibit better efficacy and less tocicity tha CA4P.
One the other hand, we know that Oxigene activelly works on second generation Combretastatin, CA1P (also called OXI4503) being the most advanced and exhibiting more potency, less toxicity and more chemical stability.
-->Does anyone is aware of competition for Squalamine?
Market Data 
Markets 
AI
